PharmaCyte acquires $3M convertible stake in Q/C Technologies; Q/C has going concern

PharmaCyte Biotech, Inc.

PharmaCyte bought Q/C Series H convertible preferred shares and warrants for $3M, convertible into 600,000 common shares each.
Q/C's auditors express substantial doubt about its ability to continue as a going concern due to net losses and negative cash flows.
Pro forma combined financials reflect the transaction; Q/C's financial statements show recurring operating losses.
Warrants expire five years after stockholder approval of issuance exceeding 19.99% of Q/C outstanding shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.